IDT's latest venture into synthetic biology marks a significant milestone in the company's growth trajectory. The unveiling of a state-of-the-art 25,000 square-foot site underscores IDT's commitment to advancing its synthetic biology operations and fortifying its position in the genomics solutions sector.
Demaris Mills, the President of IDT, emphasizes the strategic significance of the expansion, highlighting its pivotal role in shaping the future of IDT's synthetic biology product range. The increased capacity and forthcoming product enhancements, including a rapid gene synthesis offering, signify IDT's commitment to innovation and meeting the evolving needs of the global DNA synthesis market.
The new facility in Coralville is meticulously designed to optimize synthetic biology operations, with a focus on enhancing productivity and efficiency. Equipped with cutting-edge lab spaces, advanced cold storage facilities, and energy-efficient infrastructure, the site is poised to drive seamless manufacturing processes and support round-the-clock operations ([3]).
